Table 5. In vitro cumulative release (%) of NDF from the thermosensitive in situ gel formulations and the marketed product (n=3).

Time (h)	N1	N2	N3	N4	Product
0.5	4.2 ± 0.4	4.3 ± 1.2	4.5 ± 1.5	2.3 ± 0.5	7.7 ± 2.0
1	11.1 ± 0.6	10.4 ± 3.6	9.5 ± 4.5	6.1 ± 1.5	11.9 ± 2.9
2	27.6 ± 1.4	27.6 ± 8.6	24.6 ± 6.2	18.2 ± 2.3	20.4 ± 4.0
3	42.9 ± 2.9*	43.9 ± 12.3	43.8 ± 4.4	27.0 ± 5.5	27.2 ± 3.9
4	51.4 ± 5.4*	57.7 ± 3.1***	58.2 ± 4.7	35.8 ± 3.2	28.5 ± 1.4
6	76.9 ± 4.4	74.5 ± 3.7	70.8 ± 11.1	65.1 ± 15.8	37.0 ± 1.4
8	96.1 ± 11.8*	95.1 ± 7.4*	92.4 ± 2.3**	77.5 ± 8.7	42.8 ± 5.1
24	100.5 ± 1.3**	100.2 ± 1.9***	98.8 ± 2.6	98.5 ± 0.6	78.9 ± 2.4
30	100.5 ± 1.3**	100.2 ± 5.0	103.6 ± 1.7	98.5 ± 0.5	90.5 ± 0.5
46	100.5 ± 1.3	100.2 ± 7.0	102.9 ± 0.1	98.5 ± 0.5	102.5 ± 2.3

Values are expressed as mean ± standard deviation (n = 3). Statistical comparisons were performed by two-way ANOVA followed by Dunnett’s multiple comparisons test, with each formulation compared against the marketed product at every sampling time.

*p < 0.05, **p < 0.01, ***p < 0.001 versus the marketed product. Absence of a symbol indicates no statistically significant difference.

ANOVA, analysis of variance.